ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0029

Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts

Nozima Aripova1, Michael Duryee1, Carlos Hunter1, Breanna Butler1, Amy Nelson1, Bryant England1, James O'Dell1, Jill Poole1, Geoffrey Thiele1 and Ted R Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Fibroblasts, Other, interstitial lung disease, macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0013–0039.5) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Cellular interactions between alveolar macrophages (MΦ) and human lung fibroblasts (HLFs) contribute to excessive pro-inflammatory and pro-fibrotic responses in rheumatoid arthritis interstitial lung disease (RA-ILD), leading to pulmonary fibrosis. Our laboratory has previously shown that malondialdehyde-acetaldehyde (MAA) and citrulline (CIT) modifications co-localize in the lung tissue of RA-ILD patients. However, the mechanism by which MAA and CIT modified proteins alter cellular interactions between MΦ and HLFs has not been well delineated. The purpose of this study was to identify fibrotic gene expression and activation of signaling pathways by HLFs in response to: 1) macrophage supernatants (MΦ-SN) collected post-stimulation with MAA and/or CIT modified fibrinogen (FIB); or, 2) direct stimulation with MAA and/or CIT modified FIB.

Methods: Primary HLFs were treated with either MAA and/or CIT modified FIB or with MΦ-SN collected from PMA-activated U-937 cells following stimulation with MAA/CIT modified FIB. RNA was isolated 8-hours post-treatment and evaluated for the expression of 770 genes using the NanoString® Human Fibrosis Panel. The top 30 genes with the highest values for fold increase (compared to FIB or MΦ-SNFIB) were categorized into four stages (inflammation, initiation, modification, and proliferation) in the Nanostring® software based on their role in the fibrotic pathway, with several genes exerting influence on multiple pathways. Additionally, HLFs were evaluated by Western Blot for phosphorylation of signaling pathways involved in fibrosis.

Results: Treatment ofHLFs with MΦ-SN upregulated pro-fibrotic genes in all 4 pathways beyond the effects of direct antigen stimulation (Fig.1). For inflammatory genes, exposure of HLFs to MΦ-SNFIB-MAA-CIT yielded the highest mRNA fold increase vs. other groups. The top 5 inflammatory genes expressed following stimulation with MΦ-SNFIB-MAA-CIT vs. MΦ-SNFIB were CD36 (9-fold; critical in fibroblast activation), C8A (8-fold; component of complement system), BST2 (7-fold; bone marrow stromal antigen), BPM-10 (6-fold; bone morphogenic protein belonging to TGF-b family), MMP9 (5-fold; plays a role in matrix remodeling). The top genes for initiation, modification, and proliferation upregulated in the MΦ-SNFIB-MAA-CIT group were; CETP (14-fold), TJP2 (7-fold), and CD36 (9-fold), respectively. HLFs treated with MΦ-SNFIB-MAA-CIT in comparison to MΦ-SNFIB-MAA and MΦ-SNFIB-CIT showed an increased expression of phosphorylated; (p-) JNK (p < 0.001 vs. MF-SNFIB), p-Erk1/2 (p < 0.0001), p-Akt (p < 0.0001), and p-FAK (p < 0.0001) (Fig.2). Direct antigen stimulation did not upregulate any of the signaling pathways examined (data not shown).

Conclusion: Our studies demonstrate that HLF interaction with MΦ released mediators, particularly those initiated by exposure to dually modified antigens, are necessary to engage all 4 relevant pathways involved in fibroblast-mediated pulmonary fibrosis that characterizes RA-ILD. Identification of MΦ released soluble factors may serve as an important mediator of the inflammatory and fibrotic processes underlying RA-ILD pathogenesis and could serve as a potential novel target for treatment.

Supporting image 1

Figure 1. Representative top 5 genes from Nanostring Human Fibrosis Panel for mRNA levels of inflammation, initiation, modification, and proliferation fibrosis markers from stimulated HLF cells. HLF cells were stimulated with either supernatants from modified antigens-treated U937 cells or with directly modified antigens. The data is represented as the relative quantity (Rq) of fibrosis markers. The blue color represents an increase in mRNA levels, while the yellow color represents a decrease.

Supporting image 2

Figure 2. Phosphorylation of fibrosis signaling pathways in stimulated HLF cells. HLF cells were incubated with Mϕ-SN for 90 minutes. Mϕ-SN were collected from U-937 activation with the modified fibrinogen antigens. (A) Representative Western Blots of HLF lysates probed with signaling molecule antibodies. (B) Densitometry of normalized values (mean with SEM) to β-actin of signaling molecules. Comparisons made to FIB are illustrated above each bar: ¶¶¶¶p<0.0001; n=3. Only significant differences between groups are illustrated: ***p<0.001, ****p<0.0001.


Disclosures: N. Aripova: None; M. Duryee: None; C. Hunter: None; B. Butler: None; A. Nelson: None; B. England: Boehringer-Ingelheim, 2, 5; J. O'Dell: None; J. Poole: AstraZeneca, 12, I have received no monies. I received anti-IL-33 monoclonal antibody from AstraZeneca for animal research sutdies.; G. Thiele: None; T. Mikuls: Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9.

To cite this abstract in AMA style:

Aripova N, Duryee M, Hunter C, Butler B, Nelson A, England B, O'Dell J, Poole J, Thiele G, Mikuls T. Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/post-translationally-modified-fibrinogen-activated-macrophages-drive-the-expression-of-fibrotic-genes-in-human-lung-fibroblasts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-translationally-modified-fibrinogen-activated-macrophages-drive-the-expression-of-fibrotic-genes-in-human-lung-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology